Browse the evidence

Lifestyle interventions remain critical for optimizing body composition (preserving lean mass) and improving cardiovascular fitness, outcomes that AOMs alone do not fully address.

When using AOMs, prioritize protein intake and resistance/cardio exercise. This ensures you lose fat rather than muscle and improves your heart health, maximizing the 'quality' of the weight loss.

Achieving a total body weight loss of 5% or higher in individuals with type 2 diabetes and obesity significantly improves glycemic control (reducing HbA1c) and reduces the utilization of glucose-lowering medications.

If you have type 2 diabetes and are overweight or obese, aiming to lose at least 5% of your body weight is a critical first step. This modest loss can significantly improve your blood sugar levels and may allow you to reduce your diabetes medications. Focus on sustainable lifestyle changes involving diet, exercise, and behavioral support rather than just medication adjustments.

Achieving a total body weight loss of 10% or more in individuals with type 2 diabetes leads to progressive improvements in glycemic control and cardiometabolic risk factors, and may be necessary to reduce mortality.

If you have type 2 diabetes, aiming for 10% or more weight loss can provide even greater benefits for your heart health and longevity than the standard 5% goal. This may require more intensive lifestyle changes or medical support, but the potential to reduce cardiovascular events and death makes it a worthwhile target for many patients.

Bodybuilding coaches consistently recommend Creatine and Fish Oils as top supplements, while recommending specific Performance-Enhancing Drugs (Testosterone, Primobolan, GH) for enhanced athletes, highlighting a significant gap between evidence-based supplementation and the lack of safety data for PEDs.

Creatine (3-10 g/day) and Fish Oils are the most recommended supplements by bodybuilding coaches. Creatine is well-supported for strength and muscle gains. Fish oils support general health and may mitigate lipid issues from PEDs. For enhanced athletes, coaches recommend Testosterone, Primobolan, and Growth Hormone, but there is limited safety data on these high-dose regimens in healthy athletes.

Adherence to a diet characterized by high Food Compass 2.0 scores (indicating encouragement of minimally processed foods, legumes, nuts, and seafood, and minimization of ultra-processed foods, added sugars, and artificial additives) is associated with significantly lower risks of cardiovascular disease, cancer, lung disease, metabolic syndrome, and all-cause mortality.

Use the Food Compass 2.0 framework to guide your food choices: prioritize foods scoring 70+ (like seafood, legumes, nuts, vegetables, and fruits), consume foods scoring 31-69 (like meat, poultry, eggs, and dairy) in moderation, and minimize foods scoring 30 or below (like sugary beverages, processed cereals, and many snacks). This approach focuses on nutrient density, fiber, and minimizing added sugars and artificial additives, rather than just avoiding 'processed' foods.

A multicomponent workplace-based Mediterranean diet intervention significantly improves adherence to Mediterranean diet principles in career firefighters over 12 months.

To improve your diet, don't just rely on knowing what to eat. Change your environment. Make healthy food cheaper and more available (discounts, samples). Get your family and coworkers involved. Use reminders and cooking demos to make the new habits easier to stick with over the long term.

High-quality protein-based multi-ingredient supplementation (MIS) containing whey/casein, creatine, vitamin D, calcium, and fish oil significantly mitigates anabolic resistance in obese older adults, whereas low-quality protein (collagen) fails to support lean mass or strength gains despite matching total protein intake.

For older adults with excess body fat, simply eating enough protein is not enough to build muscle. You need high-quality protein sources (whey/casein) that are rich in leucine and essential amino acids. Combining this with creatine, vitamin D, and omega-3s is significantly more effective than using low-quality proteins like collagen, even if the total protein grams are the same.

Fortifying plant-based protein blends with leucine to match the leucine content of whey protein stimulates muscle protein synthesis (MPS) to an equivalent extent as whey protein in young healthy adults.

If you are using plant-based protein, ensure it is fortified with leucine or is a blend designed to match the leucine content of whey protein. A 20g dose of such a fortified plant protein will stimulate muscle protein synthesis just as effectively as 20g of whey protein in young, healthy adults.

Combining GLP-1 receptor agonists (GLP-1RAs) with lifestyle modifications results in significantly greater weight loss and improved cardiometabolic biomarkers compared to lifestyle modifications alone in adults with overweight or obesity.

If you have overweight or obesity, combining a GLP-1 receptor agonist (like semaglutide or liraglutide) with lifestyle changes (calorie restriction and regular exercise) is significantly more effective for weight loss and improving heart health markers than lifestyle changes alone. To minimize muscle loss, ensure your lifestyle intervention includes resistance training. Consult a doctor to determine if GLP-1RAs are appropriate for you.

Intensive lifestyle intervention (ILI) reduces cardiovascular event risk in adults with overweight/obesity and type 2 diabetes ONLY when the patient maintains at least 50% of the time in the target weight loss range (>50% TIR) after initial weight loss.

For adults with type 2 diabetes and obesity, the cardiovascular benefits of lifestyle changes (diet and exercise) are not guaranteed by weight loss alone; they are contingent on maintaining that weight loss. If you lose weight but regain it, you may not see the expected reduction in heart disease risk. Therefore, the primary goal of lifestyle intervention should be long-term weight maintenance, not just initial loss.

Multidisciplinary interventions combining diet, physical activity, pharmacological treatments, and bariatric surgery are required to effectively reduce cardiovascular risk and mortality in obese patients, as lifestyle changes alone are often insufficient.

Do not rely on diet and exercise alone to manage obesity-related heart risks. Because relapse is common with lifestyle changes alone, you should seek a multidisciplinary care plan that may include FDA-approved weight-loss medications or bariatric surgery alongside lifestyle modifications. This combined approach is the standard of care for reducing cardiovascular events and mortality in obese patients.

Adherence to treatment protocols is a critical determinant of success in obesity management, and individualized care plans are recommended to improve adherence.

Success depends on sticking to your plan. If you find yourself struggling to follow a complex regimen, ask your doctor for an individualized care plan. A multidisciplinary team (doctors, dietitians, psychologists) can tailor the approach to your life, making it easier to adhere to long-term.

Mediterranean and Vegetarian diets are effective for weight loss and cardiovascular risk reduction, with Vegetarian diets potentially lowering LDL cholesterol more effectively and Mediterranean diets lowering triglycerides more significantly.

Both Mediterranean and Vegetarian diets are effective for weight loss and heart health. If your main concern is high LDL cholesterol, a Vegetarian diet may be slightly more effective. If you are focused on lowering triglycerides, the Mediterranean diet may offer a greater benefit. Choose the one you can sustain.

Consumption of hyperprocessed foods contributes to the epidemic of obesity, diabetes, and cardiovascular disease, with risk increasing proportionally to consumption levels.

Minimize the intake of hyperprocessed foods, defined as industrial formulations with five or more ingredients. Focus on whole or minimally processed foods. Reducing consumption of these items is directly linked to lower risks of diabetes and cardiovascular disease.

Early and lifelong treatment of obesity is critical to prevent weight recurrence, preserve lean body mass, and reduce cardiometabolic risk.

Treat obesity as a chronic condition requiring lifelong management, not a short-term diet. Focus on early intervention to prevent complications and preserve muscle mass. Use comprehensive strategies including nutrition, physical activity, behavioral counseling, and medical interventions as needed. Regular follow-ups are essential to maintain health and prevent weight recurrence.

Treatment with tirzepatide (10 or 15 mg) produces a significantly greater reduction in predicted 10-year cardiovascular disease (CVD) risk compared to semaglutide (1.7 or 2.4 mg) in individuals with obesity without diabetes or prior CVD.

If you have obesity and are at risk for heart disease but don't have diabetes, tirzepatide may offer better long-term heart protection than semaglutide. It is taken as a weekly injection and has been shown to reduce your predicted 10-year risk of cardiovascular events more than semaglutide. Discuss with your doctor if this medication is appropriate for your specific health profile.

Intensive glycemic control (HbA1c <6.5%) in the first year after diagnosis of Type 2 Diabetes significantly reduces the 10-year risk of microvascular and macrovascular complications compared to higher HbA1c levels.

If you were just diagnosed with Type 2 Diabetes, ask your doctor about getting your blood sugar under tight control (HbA1c <6.5%) as soon as possible. This early, intensive treatment significantly reduces your risk of developing serious complications like kidney disease, heart problems, and vision loss over the next 10 years.

Tirzepatide treatment produces significant body weight, waist circumference, and waist-to-height ratio reductions in women across all reproductive stages (premenopausal, perimenopausal, and postmenopausal), demonstrating efficacy irrespective of menopausal status.

If you are a woman with overweight or obesity, whether you are premenopausal, perimenopausal, or postmenopausal, tirzepatide (15mg weekly) is highly effective for significant weight loss. Do not assume your reproductive stage limits your ability to lose weight with this treatment; the data shows robust results across all stages.

Weight loss of at least 10% of total body weight reverses steatohepatitis and improves histologic fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).

To reverse liver inflammation and scarring, you need to lose at least 10% of your body weight. While losing just 3-5% helps reduce liver fat, it is not enough to fix the underlying disease. Focus on sustainable dietary changes and regular exercise to reach this higher threshold.

Bariatric surgery (sleeve gastrectomy, gastric bypass, duodenal switch) provides superior long-term total weight loss (23.4%–40.7%) compared to GLP-1 receptor agonists (up to 25.3% with tirzepatide).

If your primary goal is maximum, durable weight loss, bariatric surgery currently outperforms GLP-1 medications in long-term results. However, surgery requires accepting permanent anatomical changes and potential risks. GLP-1s offer a less invasive alternative with significant weight loss, but require lifelong adherence to avoid regain and manage side effects. Choose based on your tolerance for invasiveness versus daily medication burden.

Bariatric surgery (specifically sleeve gastrectomy and Roux-en-Y gastric bypass) achieves sustained weight loss and high rates of type 2 diabetes remission, while also significantly improving or resolving obstructive sleep apnea and metabolic dysfunction-associated steatotic liver disease (MASLD).

If you have severe obesity with diabetes or sleep apnea, bariatric surgery (sleeve or bypass) is the most effective current treatment for reversing these conditions. It offers the best chance for diabetes remission and resolving sleep apnea, though you must be monitored for potential liver issues if you lose weight too quickly.

GLP-1 and GIP/GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) and emerging triple agonists (e.g., retatrutide) significantly reduce body weight, improve glycemic control, and reverse hepatic steatosis in patients with obesity and type 2 diabetes.

GLP-1 and GIP/GLP-1 agonists (like semaglutide and tirzepatide) are highly effective for weight loss and reversing liver fat in people with obesity and diabetes. They work by mimicking gut hormones to reduce appetite and improve insulin sensitivity. Triple agonists (like retatrutide) are showing even greater promise for liver fat normalization.

Tirzepatide 15 mg once weekly produces statistically significant greater reductions in body weight, BMI, and HbA1c compared to semaglutide 2.4 mg once weekly in patients with type 2 diabetes and obesity/overweight.

For patients with type 2 diabetes and obesity, tirzepatide 15mg once weekly is a more effective option for weight loss and blood sugar control than semaglutide 2.4mg. This treatment must be combined with a reduced-calorie diet and regular physical activity. Patients should be aware that while tirzepatide 15mg is more effective, it may have a slightly higher risk of gastrointestinal side effects compared to semaglutide 10mg, though both are generally well-tolerated.

Tirzepatide 15 mg provides statistically significant improvements in cardiometabolic risk factors, including waist circumference, fasting plasma glucose, and triglycerides, compared to semaglutide 2.4 mg.

Beyond weight loss, tirzepatide 15mg offers superior benefits for heart health markers like waist size, blood sugar (fasting), and triglycerides compared to semaglutide 2.4mg. This makes it a strong option for patients concerned about cardiovascular risk factors associated with obesity and diabetes.